The expanding therapeutic perspective of CCR5 blockade

Research output: Contribution to journalShort survey

7 Citations (Scopus)

Abstract

CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling HIV-1 entry into target cells. However, over time, CCR5 has witnessed an impressive transition from being considered rather unimportant in physiology and pathology to becoming central in a growing number of pathophysiological conditions. It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering with CCR5, and the subsequent production of chemokine ligand variants, small chemical compounds, and other molecular entities and strategies, may set the therapeutic standards for a wealth of different pathologies. Expressed on various cell types, CCR5 plays a vital role in the inflammatory response by directing cells to sites of inflammation. Aside HIV-1, CCR5 has been implicated in other infectious diseases and non-infectious diseases such as cancer, atherosclerosis, and inflammatory bowel disease. Individuals carrying the CCR5Δ32 mutation live a normal life and are warranted a natural barrier to HIV-1 infection. Therefore, CCR5 antagonism and gene-edited knockout of the receptor gained growing interest for the therapeutic role that CCR5 blockade may play in the attenuation of the severity or progression of numerous diseases.

Original languageEnglish
Article number1981
JournalFrontiers in Immunology
Volume8
Issue numberJAN
DOIs
Publication statusPublished - Jan 12 2018

Fingerprint

HIV-1
Chemokines
Pathology
Ligands
Gene Knockout Techniques
Therapeutics
Inflammatory Bowel Diseases
HIV Infections
Communicable Diseases
Disease Progression
Atherosclerosis
Inflammation
Mutation
Neoplasms

Keywords

  • Cancer
  • CCL5
  • CCR5
  • HIV-1
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The expanding therapeutic perspective of CCR5 blockade. / Vangelista, Luca; Vento, Sandro.

In: Frontiers in Immunology, Vol. 8, No. JAN, 1981, 12.01.2018.

Research output: Contribution to journalShort survey

@article{b731e14415414831b6b5e984f0b84915,
title = "The expanding therapeutic perspective of CCR5 blockade",
abstract = "CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling HIV-1 entry into target cells. However, over time, CCR5 has witnessed an impressive transition from being considered rather unimportant in physiology and pathology to becoming central in a growing number of pathophysiological conditions. It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering with CCR5, and the subsequent production of chemokine ligand variants, small chemical compounds, and other molecular entities and strategies, may set the therapeutic standards for a wealth of different pathologies. Expressed on various cell types, CCR5 plays a vital role in the inflammatory response by directing cells to sites of inflammation. Aside HIV-1, CCR5 has been implicated in other infectious diseases and non-infectious diseases such as cancer, atherosclerosis, and inflammatory bowel disease. Individuals carrying the CCR5Δ32 mutation live a normal life and are warranted a natural barrier to HIV-1 infection. Therefore, CCR5 antagonism and gene-edited knockout of the receptor gained growing interest for the therapeutic role that CCR5 blockade may play in the attenuation of the severity or progression of numerous diseases.",
keywords = "Cancer, CCL5, CCR5, HIV-1, Inflammation",
author = "Luca Vangelista and Sandro Vento",
year = "2018",
month = "1",
day = "12",
doi = "10.3389/fimmu.2017.01981",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

TY - JOUR

T1 - The expanding therapeutic perspective of CCR5 blockade

AU - Vangelista, Luca

AU - Vento, Sandro

PY - 2018/1/12

Y1 - 2018/1/12

N2 - CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling HIV-1 entry into target cells. However, over time, CCR5 has witnessed an impressive transition from being considered rather unimportant in physiology and pathology to becoming central in a growing number of pathophysiological conditions. It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering with CCR5, and the subsequent production of chemokine ligand variants, small chemical compounds, and other molecular entities and strategies, may set the therapeutic standards for a wealth of different pathologies. Expressed on various cell types, CCR5 plays a vital role in the inflammatory response by directing cells to sites of inflammation. Aside HIV-1, CCR5 has been implicated in other infectious diseases and non-infectious diseases such as cancer, atherosclerosis, and inflammatory bowel disease. Individuals carrying the CCR5Δ32 mutation live a normal life and are warranted a natural barrier to HIV-1 infection. Therefore, CCR5 antagonism and gene-edited knockout of the receptor gained growing interest for the therapeutic role that CCR5 blockade may play in the attenuation of the severity or progression of numerous diseases.

AB - CCR5 and its interaction with chemokine ligands have been crucial for understanding and tackling HIV-1 entry into target cells. However, over time, CCR5 has witnessed an impressive transition from being considered rather unimportant in physiology and pathology to becoming central in a growing number of pathophysiological conditions. It now turns out that the massive efforts devoted to combat HIV-1 entry by interfering with CCR5, and the subsequent production of chemokine ligand variants, small chemical compounds, and other molecular entities and strategies, may set the therapeutic standards for a wealth of different pathologies. Expressed on various cell types, CCR5 plays a vital role in the inflammatory response by directing cells to sites of inflammation. Aside HIV-1, CCR5 has been implicated in other infectious diseases and non-infectious diseases such as cancer, atherosclerosis, and inflammatory bowel disease. Individuals carrying the CCR5Δ32 mutation live a normal life and are warranted a natural barrier to HIV-1 infection. Therefore, CCR5 antagonism and gene-edited knockout of the receptor gained growing interest for the therapeutic role that CCR5 blockade may play in the attenuation of the severity or progression of numerous diseases.

KW - Cancer

KW - CCL5

KW - CCR5

KW - HIV-1

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85040518638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040518638&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.01981

DO - 10.3389/fimmu.2017.01981

M3 - Short survey

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JAN

M1 - 1981

ER -